Mydecine Innovations Group Bolsters Board with Key Appointments
Vancouver, British Columbia -- March 26, 2025 -- NewsGenie -- Mydecine Innovations Group Inc. has announced the appointment of Peter Field and Michael Callas to its board of directors, effective March 18 and March 21, 2025, respectively. Field, an entrepreneur with 30 years of experience in business development and technology ventures, brings expertise in GMP manufacturing, biotech investments, and public markets. Callas, founder and CEO of EVOOAI, is known for his work in preserving human creativity in the AI sector and has held leadership roles at Vacuumlabs, EY, and Vodafone. He also has experience fostering innovation and mentoring entrepreneurs. These appointments follow the resignation of Robert Roscow. Additionally, Damon Michaels has resigned as Chief Operating Officer, effective January 22, 2025. Mydecine has expressed gratitude for Roscow and Michaels' contributions. Mydecine Innovations Group focuses on developing medications and therapies for mental health disorders, blending advanced technology with drug discovery.